Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function
Completed · Phase 1
Conditions studied: Renal Impairment
In brief
Evaluation of the pharmacokinetics (PK) of TBPM-PI-HBr in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.
Key facts
- Study ID
- NCT04178577
- Run by
- Spero Therapeutics
- People needed
- 39
- Starts
- 2019-12-06
- Expected to finish
- 2020-09-11
- Last updated by the study team
- 2020-11-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Medical Facility — Miami, Florida, United States
- Medical Facility — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.